Thursday, November 5, 2020

Protomer Technologies Gets Funding For Protein Therapeutics

Pasadena-based Protomer Technologies announced this morning that it has received funding from both the JDRF T1D Fund, as well as Eli Lilly and Company, in a funding round. Size of the investment was not announced. The company said Eli Lilly and Company led the funding, with the new investment today from JDRF. Protomer said it is developing next-generation protein therapeutics that can sense molecular activators in the body. The company said its therapeutic candidates include a glucose responsive insulin that can sense sugar levels in the blood and automatically activate as needed throughout the day. Protomer is led by CEO Alborz Mahdavi. More information »